VRDN News and Press, Viridian Therapeutics Inc Com From 04/25/24

2024-04-25 12:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...

2024-03-20 15:15:02 ET Needham analyst issues UNDERPERFORM recommendation for VRDN on March 20, 2024 02:00PM ET. The previous analyst recommendation was Underperform. VRDN was trading at $17.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Confer...

2024-02-28 10:15:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for VRDN on February 28, 2024 09:00AM ET. The previous analyst recommendation was Underperform. VRDN was trading at $20.65 at issue of the analyst recommendation. The overall analyst consensus ...

- VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and year-end 2024, respectively - - Subcutaneous VRDN-003 pivotal program in thyroid eye disease expected to start mid-year 2024 pending regulatory authority alignment, as previously share...

2024-01-18 01:55:45 ET More on Viridian Therapeutics Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 Viridian: Market May Be Wrong In Its Disapproval Viridian Therapeutics starts public offering of common and preferred stock Vir...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. Viridian i...

2024-01-17 16:17:04 ET More on Viridian Therapeutics Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 Viridian: Market May Be Wrong In Its Disapproval Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $...

- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease (TED), respectively - - Subcutaneous VRDN-003 pivotal study in TED anticipated to start in mid-2024, pending alignment with regulator...